Skip to content

Replimune Group REPL Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Immunome logo
ImmunomeIMNM
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
Arcus Biosciences logo
Arcus BiosciencesRCUS
Tango Therapeutics logo
Tango TherapeuticsTNGX
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's operating lease right-of-use asset amortization?
Replimune Group (REPL) reported operating lease right-of-use asset amortization of $194K in Q4 2025.
How has Replimune Group's operating lease right-of-use asset amortization changed year-over-year?
Replimune Group's operating lease right-of-use asset amortization increased by 12.1% year-over-year, from $173K to $194K.